1.. Introduction {#S0001}
================

Acute pancreatitis is the most common gastrointestinal cause of hospitalization \[[1](#CIT0001)\]. The rate of hospitalization continues to grow \[[2](#CIT0002)\]. Analysis of national inpatient sample databases showed a 33% increase in acute pancreatitis-related hospitalization over a 7-year period from 1997 to 2003 \[[3](#CIT0003)\]. The rise in incidence of acute pancreatitis is probably a result of a combination of increasing incidence of risk factors such as obesity (gallstone disease) and more testing \[[4](#CIT0004)\].

The severity of acute pancreatitis is the major determinant of clinical outcomes with mortality ranging from 1--3% in mild to over 20% in severe acute pancreatitis (SAP), defined by the presence and persistence of organ failure \[[5](#CIT0005),[6](#CIT0006)\]. A major challenge for care providers is to predict the development of severe pancreatitis early in the course, which would improve patient management and resource utilization. But most of the patients who develop severe pancreatitis during hospitalization present to the emergency room without organ failure initially, and no single laboratory test has been shown to reliably predict subsequent progression to severe pancreatitis. Therefore, an accurate clinical prediction rule has the potential to dramatically improve the management of acute pancreatitis.

The Bedside Index for Severity in Acute Pancreatitis (BISAP) was developed in 2008 \[[7](#CIT0007)\]. It is an easy to calculate from data points available in the first 24 hours of presentation to emergency department ([Box 1](#S0005)). Other clinical prediction scores reported in the literature are cumbersome to calculate, need clinical and laboratory data from 48 hours of hospitalization and do not outperform BISAP in predicting severe pancreatitis \[[8](#CIT0008),[9](#CIT0009)\]. This is all the more relevant since the first 24--48 hour period is the most crucial time window in management of pancreatitis, and by the end of 48 hours most patients have revealed the severity of their illness with clinical improvement or development of organ failure.

Multiple studies have validated the performance of the BISAP in predicting acute severe pancreatitis. A systematic review for accurate estimation of the predictive performance of the BISAP can provide an objective and quantitative estimate to complement clinical assessment in acute pancreatitis. Multiple prospective studies have been published since a systematic review was published \[[10](#CIT0010)\]. We thus have aimed to perform a comprehensive systematic review and meta-analysis to assess the predictive performance of the BISAP for SAP.

1.1.. Methods {#S0001-S2001}
-------------

The reporting guidelines of Meta-analysis of Observational Studies in Epidemiology (MOOSE) were followed in this systematic review and meta-analysis \[[11](#CIT0011)\].

### 1.1.1.. Search {#S0001-S2001-S3001}

The search was performed in the first week of October 2015 by one of the investigators (S.C.) who has prior experience in performing searches for systematic reviews. Major databases of biomedical publications (Medline, Scopus and Web of Science) were included. The period of search was limited to 2008--2015, as the BISAP was developed in 2008. Language restrictions were not applied. Details of the search strategy are described in Appendix 1. Reference lists of the eligible studies were searched to identify additional studies.

### 1.1.2.. Study selection {#S0001-S2001-S3002}

We included studies that reported the predictive performance of the BISAP for SAP from prospective cohorts of patients hospitalized for acute pancreatitis. Retrospectives studies and studies not based on original data or published in abstract format only were excluded. Studies published in a non-English language were included in data-synthesis for quantitative analysis but excluded from the methodology quality assessment.

Studies were searched in two phases, by two independent reviewers (A.M., R.B.). In phase I, study titles and abstracts were screened for eligibility. Full reports of studies deemed eligible by either reviewer in phase I were obtained. In phase II, both reviewers assessed the full text of each study for eligibility. Disagreements were resolved by consensus in the presence of the third reviewer (S.C.).

### 1.1.3.. Methodology quality assessment {#S0001-S2001-S3003}

The quality assessment parameters for study methodology were adopted from McGinn et al.'s users' guide \[[12](#CIT0012)\]. These parameters assess patient selection for clinical and demographic characteristics, severity of the disease, accurate interpretation of the predictors and the outcomes (mutually blinded) and adequate follow-up (defined as available in \>95% of enrolled subjects). Two reviewers performed quality assessment, independently (S.C., A.M.). Disagreements were resolved by consensus.

### 1.1.4.. Data extraction {#S0001-S2001-S3004}

Two reviewers (S.C., A.M.) extracted data from all the included studies. A standardized electronic data-extraction datasheet was used. Because most of the studies did not report number of patients and outcomes for each BISAP score, the area under the receiver operating curve (AUC) was collected. The clinical outcome of interest was SAP. Acute severe pancreatitis is defined based on the presence of organ failure (Atlanta classification) or persistence of organ failure for more than 48 hours (revised Atlanta classification) \[[13](#CIT0013),[14](#CIT0014)\].

### 1.1.5.. Data synthesis and analysis {#S0001-S2001-S3005}

Pooled area under the AUC was calculated to determine BISAP's predictive performance. MedCalc statistical software (Version 17.4.4) was used to calculate the pooled AUC using a random effects model. Heterogeneity among the studies was assessed using Cochran's *Q* test and *I* ^2^ statistics. A *p* value \<0.1 was considered significant for heterogeneity. An a priori subgroup analysis was performed for severe pancreatitis rate (\<20% and 20% or higher) and definition of SAP, based on the Atlanta classification versus the revised Atlanta classification. Funnel plot analysis was used to address heterogeneity.

2.. Results {#S0002}
===========

2.1.. Study selection {#S0002-S2001}
---------------------

The study selection process is summarized in [Figure 1](#F0001). A total of 12 validation studies were included in data synthesis and quality assessment of the study methodology was performed for 10 studies.Figure 1.Flow diagram of the study selection process.

2.2.. Characteristics of the included studies {#S0002-S2002}
---------------------------------------------

The characteristics of individual studies are summarized in [Table 1](#T0001). Twelve studies encompassing a total of 3069 patients were included in data synthesis for the meta-analysis. Three cohorts were from India, two from the USA, two from Peru and one each from South Korea, China, Pakistan, Poland and Serbia. All the patients were hospitalized with a diagnosis of acute pancreatitis. Sixty percent of the patients were male. Average age ranged from 39 years to 61 years.Table 1.Characteristics of included studies and performance of the Bedside Index for Severity in Acute Pancreatitis (BISAP) score.StudyCountry*N*Male (%)Mean age (yrs)Alcoholic (%)Gallstone (%)SAP (%)Yadav 2015India1197139403135.3Mok 2015USA2665949372615.4Campos 2015Peru33430421878.4Bezmareviu 2012Serbia516761222856.9Bollen 2012USA1505654234819.3Khanna 2013India725141184443.1Kim 2013Korea506860462448.0Senapati 2014India2466242532815.9Surco 2012Peru32965NANA7427.1Yu 2014China3587747NANA15.4Shabbir 2015Pakistan804447NANA31.3Koziel 2015Poland1014635427346.9**Pooled** **306960**   **16**[^1]

2.3.. Methodology quality assessment {#S0002-S2003}
------------------------------------

Scoring of individual studies on methodology quality assessment parameters is presented in [Table 2](#T0002). All the studies had enrolled a consecutive cohort of patients hospitalized with a diagnosis of acute pancreatitis and included a broad spectrum of the disease severity. Follow-up was adequate in all the reviewed studies. Explicit and accurate interpretation of the predictor was reported in each study. The outcome of interest (SAP) was well defined in each study. Six studies used the Atlanta classification \[[15](#CIT0015)--[20](#CIT0020)\] and the other six used the revised Atlanta classification \[[21](#CIT0021)--[26](#CIT0026)\]. Blinded outcome assessment was reported in only one study \[[17](#CIT0017)\].Table 2.Methodology quality assessment of included studies.ParametersYadav 2015Bezmareviu 2012Senapati 2014Kim 2013Khanna 2013Bollen 2012Moke 2015Shabbir 2015Koziel 2015Campos 20151. Patients chosen in unbiased fashion representing wide spectrum of severity of disease.YYYYUYYYYY2. Blinded assessment of the criterion standard for all the patients.NRNRNRNRNRYNRNRNRNR3. Explicit and accurate interpretation of the predictor.YYYYYYYYYY4. 100% follow-up on those enrolled.YYYYYYYYYY[^2]

2.4.. Predictive performance of BISAP {#S0002-S2004}
-------------------------------------

Of the 3069 patients from the included studies, 16% of patients developed SAP. The pooled AUC was 0.84 (95% CI, 0.79--0.90); see [Figure 2](#F0002). There was significant heterogeneity in pooled estimates, *I* ^2^ 91%, *p* \< 0.001. A funnel plot showed significant asymmetry ([Figure 3](#F0003)). The distribution of asymmetry is consistent with publication bias \[[27](#CIT0027)\].Figure 2.Pooled area under the receiver operating curve to demonstrated prognostic performance of the Bedside Index for Severe Acute Pancreatitis, 0.84 (95%, 0.79--0.90. Figure 3.Funnel plot showing assymetry which represents probable publication bias.

2.5.. Heterogeneity {#S0002-S2005}
-------------------

A priori subgroup analyses were performed to address the heterogeneity. Studies were grouped based on the prevalence of SAP (\<20% and 20% or higher) and definition used for SAP, 1992 Atlanta classification versus the revised Atlanta classification. In studies with an SAP rate of \>20%, the pooled AUC was 0.86 (95% CI, 0.79--0.93) with *I* ^2^ 84% and 0.83 (95% CI, 0.75--0.90) with *I* ^2^ 94% in studies with \<20%. The pooled AUC from studies using the revised Atlanta classification was 0.87 (95% CI, 0.80--0.94), *I* ^2^ 92%, *p* \< 0.001. Studies using the original Atlanta classification had a pooled AUC of 0.81 (95% CI, 0.74--0.88), *I* ^2^ 86% *p* \< 0.001. Since heterogeneity still persisted, a funnel plot was constructed for studies using the revised Atlanta classification and outlier studies were excluded. Both of the excluded studies had a remarkably low rate of SAP, 6.9% and 8.4% \[[24](#CIT0024),[25](#CIT0025)\]. The pooled AUC from the remaining four studies using the revised Atlanta classification was 0.92 (95% CI, 90--95), but heterogeneity persisted, *I* ^2^ 67% *p* = 0.029,

3.. Discussion {#S0003}
==============

In this systematic review and meta-analysis, a pooled analysis from 12 prospective cohorts demonstrated very good performance of BISAP for predicting SAP across different patient populations and severity of disease. The performance of BISAP was higher if severe pancreatitis was defined as persistence of organ failure for 48 hours or longer.

3.1.. External validity {#S0003-S2001}
-----------------------

Twelve prospective cohorts were identified to calculate the pooled estimate. It included 3069 patients hospitalized with acute pancreatitis, of whom 491 developed SAP. Patient selection was consecutive and represented a wide range of severity of pancreatitis and varied etiologies (with gallstone and alcohol predominating). Therefore, inclusion of a good mix of etiology, pancreatitis severity and patient demographics with a large number of patients ensures excellent external validity of pooled estimates from this study.

3.2.. Strengths and limitations {#S0003-S2002}
-------------------------------

The strengths of this study include a search strategy that included three major databases of biomedical publications without any language restrictions and searching the bibliographies of the included studies. We used a robust method in conducting systematic reviews and two reviewers performed the study selection, data extraction and the methodology quality assessment of the included studies. Including prospective cohorts ensured accurate assessment of predictors because for most patients the eventual diagnostic outcome was not available at the time of predictor assessment.

This study was limited by relatively small numbers of studies being available in the literature, limited reporting of data and heterogeneity between the studies. This limits the quality of the evidence and ability to perform analysis at different cut-off points to determine sensitivity and specificity. There is probable publication bias. Efforts were made to minimize the publication bias, which included not using language restriction in the search, a manual search of reference lists of included studies and the use of multiple databases. Also, a random effect model was used in calculating pooled estimates instead of a fixed effect model. A random effect model provides more conservative pooled estimates.

3.3.. Clinical implications and future direction {#S0003-S2003}
------------------------------------------------

The BISAP is an easy-to-calculate clinical prediction scale using data from the initial clinical assessment of patients and routine laboratory data. Pooled estimates in the current study demonstrate its very good performance in predicting severe acute pancreatitis. The ease of calculation and accuracy make the BISAP a valuable tool for clinical providers caring for patients with acute pancreatitis. An implementation study is important before widespread adoption of a clinical prediction score can be recommended \[[28](#CIT0028)\]. To date, no studies have reported the impact of incorporating the BISAP into clinical practice to improve outcome in the management of acute pancreatitis, and further research in this area is warranted.

 {#S0004}

Box 1. Variables included in Bedside Index of Severity in Acute Pancreatitis (BISAP) score.Blood urea nitrogen \> 25 mg/dlAbnormal mental status (Glasgow coma score \<15)Evidence of systemic inflammatory response syndromeGreater than or equal to 60 years oldPleural effusionTo calculate the BISAP, sum the number of positive variables (0--5).
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[^1]: NA, not available; SAP, severe acute pancreatitis.

[^2]: NP, not reported; U, unclear; Y, yes.
